Sensyne Health Maiden Interim Results 2018

Sensyne Health Maiden Interim Results 2018

Oxford, UK; 28th January 2019: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the British Clinical AI technology company, today announces its Interim Results for the six months ended 31st October 2018.
January 28, 2019
Lord (Paul) Drayson, CEO of Sensyne Health, commented:

“I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones.

Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our Initial Public Offering (“IPO”). The Company is in an excellent position to capitalise on the data assets and Clinical Artificial Intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation.”

Click here to view full interim results.

  • Signing of an agreement with Jefferson Health for the clinical and economic evaluation of our GDm-Health™ digital therapeutic product and generation of curated patient data within a US hospital system
  • Conditional agreements for two further NHS Trust Strategic Research Agreements (“SRA”) with George Eliot NHS Trust and Wye Valley NHS Trust for which they will each be issued with £2.5m in ordinary shares in the Company at £1.75 per share
  • Signing of a research agreement with the Big Data Institute at the University of Oxford using Sensyne’s anonymised patient data from our existing SRAs and digital health products, focused in the field of chronic disease including chronic kidney disease (“CKD”) and cardiovascular disease

  • Increased the number of SRAs with NHS Trusts to six (four at the time of the IPO), increasing the patient population covered by our now five NHS Trust partners from c.2.5 million to c.3m, and data of an additional 2.1m patient admissions while expanding the Real World Evidence (“RWE”) population of community care and primary and secondary care integration
  • Grown the team to 70 staff in line with plan (41 at the time of the IPO) including highly skilled clinicians, data scientists and software developers
  • Progressed lead Clinical AI project (SH-001) in the field of hypertension identifying nocturnal surge in blood pressure in young and middle-aged patients
  • Developed and commenced clinical verification of a proprietary condition tracking algorithm for gestational diabetes; SYNE™ GDM/001
  • Commencing our first programme on WGS, of asthma patients in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust
  • Undertaken analysis of Phase II & Phase III clinical trial data using Clinical AI and demonstrated our electronic Clinical Research Organisation (“eCRO”) Analytics Capabilities
  • Chelsea and Westminster have undertaken an analysis of air pollution levels in an Intensive Care Unit using CleanSpace™
  • Launched scalable, cloud-based digital therapeutic product GDm-Health™ for the management of gestational diabetes mellitus (“GDM”)
  • Admitted to the AIM Market of the London Stock Exchange on 17 August 2018, raising £60m in new investment (including transaction costs of £5.5m)
  • Relocated to state-of-the-art facilities at the Schrödinger Building at the Oxford Science Park
  • Adopted and signed up to the new UK Government code of conduct for data driven health and care technologies
  • Formed a consortium with Microsoft, EY, JP Morgan and Peel Hunt and submitted a proposal to the UK Government in response to the Government’s consideration of a national, linked health data policy
  • Appointed new Interim Non-executive Chairman, Charles Swingland, after Professor Sir John Bell stepped down to avoid any potential conflicts of interest with his role advising UK Government
  • Appointed Professor Lionel Tarassenko to the role of Director of R&D and Non-Executive Director

  • Cash and cash equivalents of £57.7m at 31 October 2018
  • Cash used in operating activities of £5.7m (2017: £1.9m) for the 6 months to 31 October 2018
  • Revenues of £39k (2017: £20k) for the 6 months to 31 October 2018
  • Adjusted operating loss from continuing operations of £5.1m (2017: £2.9m), which reflects the progress made in recruitment and establishing the Sensyne Health business since formation in May 2017
  • Operating loss of £10.3m (2017: £3.4m) for the 6 months to 31 October 2018
  • Continued recruitment to support and progress increasing commercial activity is expected to lead to an increased Operating loss for the remainder of the year


Analyst and Investor briefing

Lord Drayson, Chief Executive Officer, and Lorimer Headley, Chief Financial Officer, will present the Interim Results for analysts and investors today at 10.30am GMT. There will be a simultaneous live conference call.

Dial-in detail are:

Participant local dial-in: +44 (0) 203 0095710

Participant free phone dial-in: 08003767425

Participant US free phone dial-in: +18668692321

Participant code: 6992215

A live webcast of the meeting and the presentation slides, will be available on the investor section of Sensyne Health’s website:


For more information please contact:

Sensyne Health (

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng,  Chief Executive Officer

Lorimer Headley, Chief Financial Officer

Julia Wilson, Director of Investor Relations

Peel Hunt LLP (Nominated Adviser  and Broker)

+ 44 (0) 20 7418 8900

Dr Christopher Golden 

James Steel

Oliver Jackson


Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner


About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company’s access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology’.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: